Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

References

• RobertsABLambLCNewtonDLSpornMBDe LarcoJETodaroGJTransforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extractionProc Natl Acad Sci U S A1980776349434986251462
   PubMed Web of Science ®Google Scholar
• PiekEHeldinCHTen DijkePSpecificity, diversity, and regulation in TGF-beta superfamily signalingFASEB J199913152105212410593858
   PubMed Web of Science ®Google Scholar
• AnzanoMARobertsABMeyersCASynergistic interaction of two classes of transforming growth factors from murine sarcoma cellsCancer Res19824211477647786290046
   PubMed Web of Science ®Google Scholar
• RobertsABAnzanoMALambLCSmithJMSpornMBNew class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissuesProc Natl Acad Sci U S A1981789533953436975480
   PubMed Web of Science ®Google Scholar
• MassagueJBlainSWLoRSTGFbeta signaling in growth control, cancer, and heritable disordersCell2000103229530911057902
   PubMed Web of Science ®Google Scholar
• CheifetzSWeatherbeeJATsangMLThe transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptorsCell19874834094152879635
   PubMed Web of Science ®Google Scholar
• HuangTDavidLMendozaVTGF-β signalling is mediated by two autonomously functioning TβRI:TβRII pairsEMBO J20113071263127621423151
   PubMed Web of Science ®Google Scholar
• AkhurstRJHataATargeting the TGFbeta signalling pathway in diseaseNat Rev Drug Discov2012111079081123000686
   PubMed Web of Science ®Google Scholar
• GordonKJBlobeGCRole of transforming growth factor-beta super-family signaling pathways in human diseaseBiochim Biophys Acta20081782419722818313409
   PubMed Web of Science ®Google Scholar
• YinglingJMBlanchardKLSawyerJSDevelopment of TGF-beta signalling inhibitors for cancer therapyNat Rev Drug Discov20043121011102215573100
   PubMed Web of Science ®Google Scholar
• HahnSASchutteMHoqueATDPC4, a candidate tumor suppressor gene at human chromosome 18q21.1Science199627152473503538553070
   PubMed Web of Science ®Google Scholar
• GradyWMMyeroffLLSwinlerSEMutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancersCancer Res19995923203249927040
   PubMed Web of Science ®Google Scholar
• KimWSParkCJungYSReduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lungAnticancer Res1999191A30130610226558
   PubMed Web of Science ®Google Scholar
• LevyLHillCSAlterations in components of the TGF-beta superfamily signaling pathways in human cancerCytokine Growth Factor Rev2006171–2415816310402
   PubMed Web of Science ®Google Scholar
• LamouilleSXuJDerynckRMolecular mechanisms of epithelial-mesenchymal transitionNat Rev Mol Cell Biol201415317819624556840
   PubMed Web of Science ®Google Scholar
• KehrlJHWakefieldLMRobertsABProduction of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growthJ Exp Med19861635103710502871125
   PubMed Web of Science ®Google Scholar
• FlavellRASanjabiSWrzesinskiSHLicona-LimonPThe polarization of immune cells in the tumour environment by TGFbetaNat Rev Immunol201010855456720616810
   PubMed Web of Science ®Google Scholar
• LeaskAAbrahamDJTGF-beta signaling and the fibrotic responseFASEB J200418781682715117886
   PubMed Web of Science ®Google Scholar
• HorieMSaitoANoguchiSDifferential knockdown of TGF-beta ligands in a three-dimensional co-culture tumor–stromal interaction model of lung cancerBMC Cancer20141458025107280
   PubMed Web of Science ®Google Scholar
• LoefflerMKrugerJANiethammerAGReisfeldRATargeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptakeJ Clin Invest200611671955196216794736
   PubMed Web of Science ®Google Scholar
• GoumansMJLiuZten DijkePTGF-beta signaling in vascular biology and dysfunctionCell Res200919111612719114994
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• SiegelPMMassagueJCytostatic and apoptotic actions of TGF-beta in homeostasis and cancerNat Rev Cancer200331180782114557817
   PubMed Web of Science ®Google Scholar
• PickupMNovitskiySMosesHLThe roles of TGFbeta in the tumour microenvironmentNat Rev Cancer2013131178879924132110
   PubMed Web of Science ®Google Scholar
• BiswasSCriswellTLWangSEArteagaCLInhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategyClin Cancer Res20061214 Pt 14142414616857784
   PubMed Web of Science ®Google Scholar
• BharathySXieWYinglingJMReissMCancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotypeCancer Res20086861656166618339844
   PubMed Web of Science ®Google Scholar
• HawinkelsLJGarcia de VinuesaATen DijkePActivin receptor-like kinase 1 as a target for anti-angiogenesis therapyExpert Opin Investig Drugs2013221113711383
   PubMed Web of Science ®Google Scholar
• KanoMRBaeYIwataCImprovement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signalingProc Natl Acad Sci U S A200710493460346517307870
   PubMed Web of Science ®Google Scholar
• LiuZKobayashiKvan DintherMVEGF and inhibitors of TGF-beta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expressionJ Cell Sci2009122Pt 183294330219706683
   PubMed Web of Science ®Google Scholar
• MorrisJCTanAROlenckiTEPhase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinomaPLoS One201493e9035324618589
   PubMed Web of Science ®Google Scholar
• LonningSMannickJMcPhersonJMAntibody targeting of TGF-beta in cancer patientsCurr Pharm Biotechnol201112122176218921619535
   PubMed Web of Science ®Google Scholar
• TrachtmanHFervenzaFCGipsonDSA phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosisKidney Int201179111236124321368745
   PubMed Web of Science ®Google Scholar
• StevensonJPKindlerHLPapasavvasEImmunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patientsOnco Immunology20132e26218
   Google Scholar
• CohnALahnMWilliamsKA phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancerInt J Oncol20144562221223125270361
   PubMed Web of Science ®Google Scholar
• ZhongZCarrollKDPolicarpioDAnti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cellsClin Cancer Res20101641191120520145179
   PubMed Web of Science ®Google Scholar
• BogdahnUHauPStockhammerGTargeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb studyNeuro Oncol201113113214220980335
   PubMed Web of Science ®Google Scholar
• Isarna-therapeutics.com [homepage on the Internet]Antisense Pharma Unveils its Corporate Strategy for 2013 Available from: http://www.isarna-therapeutics.com/fileadmin/user_upload/documents/press-releases/2013/20130226_EN_PressRelease_CorporateStrategy_2013.pdfAccessed March 3, 2015
   Google Scholar
• GiacconeGBazhenovaLNemunaitisJA Phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC)Presented at: Presidential Session I: Best and Late Breaking Abstracts, 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress2013Amsterdam Abstract E17-7081
   Google Scholar
• LahnMKloekerSBerryBSTGF-beta inhibitors for the treatment of cancerExpert Opin Investig Drugs2005146629643
   PubMed Web of Science ®Google Scholar
• SeoaneJThe TGFBeta pathway as a therapeutic target in cancerClin Transl Oncol2008101141918208788
   PubMed Web of Science ®Google Scholar
• GarberKCompanies waver in efforts to target transforming growth factor beta in cancerJ Natl Cancer Inst2009101241664166719933941
   PubMedGoogle Scholar
• NagarajNSDattaPKTargeting the transforming growth factor-beta signaling pathway in human cancerExpert Opin Investig Drugs20101917791
   PubMed Web of Science ®Google Scholar
• EhataSHanyuAFujimeMKi26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell lineCancer Sci200798112713317129361
   PubMed Web of Science ®Google Scholar
• JinCHKrishnaiahMSreenuDDiscovery of N-((4-([1,2,4] Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-beta type I receptor kinase as cancer immunotherapeutic/antifibrotic agentJ Med Chem201457104213423824786585
   PubMed Web of Science ®Google Scholar
• SonJYParkSYKimSJEW-7197, a novel ALK-5 Kinase inhibitor, potently inhibits breast to lung metastasisMol Cancer Ther20141371704171624817629
   PubMed Web of Science ®Google Scholar
• WranaJLAttisanoLCarcamoJTGF beta signals through a heteromeric protein kinase receptor complexCell1992716100310141333888
   PubMed Web of Science ®Google Scholar
• WieserRWranaJLJ MassagueJGS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complexEMBO J19951410219922087774578
   PubMed Web of Science ®Google Scholar
• LeofEBProperJAGoustinASShipleyGDDiCorletoPEMosesHLInduction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activityProc Natl Acad Sci U S A1986838245324573010310
   PubMed Web of Science ®Google Scholar
• SawyerJSBeightDWBrittKSSynthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domainBioorg Med Chem Lett200414133581358415177479
   PubMed Web of Science ®Google Scholar
• SawyerJSAndersonBDBeightDWSynthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domainJ Med Chem200346193953395612954047
   PubMed Web of Science ®Google Scholar
• LiHYMcMillenWTHeapCROptimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agentJ Med Chem20085172302230618314943
   PubMed Web of Science ®Google Scholar
• YinglingJMYanLLuKCharacterization or Substituted Pyrazoles as ATP-Competitive TGF-beta Receptor Kinase Inhibitors: the TGF-beta superfamilyLa Jolla (CA)American Association for Cancer Research2003
   Google Scholar
• PengSBYanLXiaXKinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transitionBiochemistry20054472293230415709742
   PubMed Web of Science ®Google Scholar
• Muraoka-CookRSShinIYiJYActivated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progressionOncogene200625243408342316186809
   PubMed Web of Science ®Google Scholar
• LiHYWangYYanLNovel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolinesBioorg Med Chem Lett200414133585358815177480
   PubMed Web of Science ®Google Scholar
• LahnMTransforming growth factor beta (TGF-beta) inhibitors and their development in the treatment of cancer3rd Cancer Drug Research and Development GTCbio2006San Francisco, CA
   Google Scholar
• StauberAJCredilleKMTruexLLEhlhardtWJYoungJKNonclinical safety evaluation of a transforming growth factor β receptor I kinase inhibitor in fischer 344 rats and beagle dogsJ Clin Pract20144196
   Google Scholar
• MatternSPThe Prince of Medicine: Galen in the Roman EmpireOxfordOxford University Press2013
   Google Scholar
• MedPacto IncFirst-in-human dose-escalation study of TEW-7197 monotherapy in subjects with advanced stage solid tumors Available from: https://clinicaltrials.gov/ct2/show/NCT02160106?term=nct02160106&rank=1. NLM identifier: NCT02160106Accessed March 3, 2015
   Google Scholar
• AndertonMJMellorHRBellAInduction of heart valve lesions by small-molecule ALK5 inhibitorsToxicol Pathol201139691692421859884
   PubMed Web of Science ®Google Scholar
• SinghJLingLESawyerJSLeeWCZhangFYinglingJMTransforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5)Curr Opin Drug Discov Devel200474437445
   PubMed Web of Science ®Google Scholar
• StauberAJZimmermannJLBerridgeBRPathobiology of a valvulopathy in fischer 344 rats given a transforming growth factor-b RI kinase inhibitorSOT 45th Annual Meeting and Tox Expo™2006San Diego (CA)Oxford University Press Abstract 290
   Google Scholar
• UebaHKawakamiMYaginumaTShear stress as an inhibitor of vascular smooth muscle cell proliferation. Role of transforming growth factor-beta 1 and tissue-type plasminogen activatorArterioscler Thromb Vasc Biol1997178151215169301628
   PubMed Web of Science ®Google Scholar
• WalsheTEdela PazNGD’AmorePAThe role of shear-induced transforming growth factor-beta signaling in the endotheliumArte-rioscler Thromb Vasc Biol2013331126082617
   Web of Science ®Google Scholar
• LoeysBLSchwarzeUHolmTAneurysm syndromes caused by mutations in the TGF-beta receptorN Engl J Med2006355878879816928994
   PubMed Web of Science ®Google Scholar
• LindsayMESchepersDBolarNALoss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysmNat Genet201244892292722772368
   PubMed Web of Science ®Google Scholar
• HolmTMHabashiJPDoyleJJNoncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome miceScience2011332602735836121493862
   PubMed Web of Science ®Google Scholar
• VilarJMJansenRSanderCSignal processing in the TGF-beta super-family ligand-receptor networkPLoS Comput Biol200621e316446785
   PubMed Web of Science ®Google Scholar
• VizanPMillerDSGoriIDasDSchmiererBHillCSControlling long-term signaling: receptor dynamics determine attenuation and refractory behavior of the TGF-beta pathwaySci Signal20136305ra10624327760
   PubMed Web of Science ®Google Scholar
• FeaginsLARole of transforming growth factor-beta in inflammatory bowel disease and colitis-associated colon cancerInflamm Bowel Dis201016111963196820848467
   PubMed Web of Science ®Google Scholar
• HongSLeeHJKimSJHahmKBConnection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signalingWorld J Gastroenterol201016172080209320440848
   PubMed Web of Science ®Google Scholar
• YinglingJTargeting the TGF-β RI kinase with LY2157299: a PK/PD-driven drug discovery and clinical development programPresented at: AACR MeetingMay 1, 2005 Abstract 1463a
   Google Scholar
• BuenoLde AlwisDPPitouCSemi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in miceEur J Cancer200844114215018039567
   PubMed Web of Science ®Google Scholar
• YinglingJMShouJXiaXA small molecule inhibitor of TGFβ RI kinase potentiates VEGF dependent angiogenesis in vitroProc Am Assoc Cancer Res2006 Abstract 250
   Google Scholar
• MaierAPeilleALVuaroqueauxVLahnMAnti-tumor activity of the TGF-beta receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenograftsCell Oncol (Dordr) Epub201519
   Web of Science ®Google Scholar
• AkhurstRJDerynckRTGF-beta signaling in cancer–a double-edged swordTrends Cell Biol20011111S44S5111684442
   PubMed Web of Science ®Google Scholar
• DerynckRAkhurstRJBalmainATGF-beta signaling in tumor suppression and cancer progressionNat Genet200129211712911586292
   PubMed Web of Science ®Google Scholar
• YangYADukhaninaOTangBLifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effectsJ Clin Invest2002109121607161512070308
   PubMed Web of Science ®Google Scholar
• LiCYWoodDKHuangJHBhatiaSNFlow-based pipeline for systematic modulation and analysis of 3D tumor microenvironmentsLab Chip201313101969197823563587
   PubMed Web of Science ®Google Scholar
• HuangSHolzelMKnijnenburgTMED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signalingCell2012151593795023178117
   PubMed Web of Science ®Google Scholar
• BholaNEBalkoJMDuggerTCTGF-beta inhibition enhances chemotherapy action against triple-negative breast cancerJ Clin Invest201312331348135823391723
   PubMed Web of Science ®Google Scholar
• SimeoniMMagniPCammiaCPredictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agentsCancer Res20046431094110114871843
   PubMed Web of Science ®Google Scholar
• RocchettiMPoggesiIGermaniMA pharmacokinetic-pharmacodynamic model for predicting tumour growth inhibition in mice: a useful tool in oncology drug developmentBasic Clin Pharmacol Toxicol200596326526815733231
   PubMed Web of Science ®Google Scholar
• BhattacharSNPerkinsEJTanJSBurnsLJEffect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus, simulations to predict absorptionJ Pharm Sci2011100114756476521681753
   PubMed Web of Science ®Google Scholar
• GueorguievaICleverlyALStauberADefining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic modelBr J Clin Pharmacol201477579680724868575
   PubMed Web of Science ®Google Scholar
• LahnMKunzmannRKohlerGComparison of cytogenetics, cytokine secretion, and oncogene expression in primary cultures of renal carcinoma cellsOncology19975454294379260606
   PubMed Web of Science ®Google Scholar
• ShariatSFShalevMMenesses-DiazAPreoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomyJ Clin Oncol200119112856286411387358
   PubMed Web of Science ®Google Scholar
• BandyopadhyayAAgyinJKWangLInhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitorCancer Res200666136714672116818646
   PubMed Web of Science ®Google Scholar
• FarringtonDLYinglingJMFillJADevelopment and validation of a phosphorylated SMAD ex vivo stimulation assayBiomarkers200712331333017453744
   PubMed Web of Science ®Google Scholar
• BaselgaJRothenbergMLTaberneroJTGF-beta signalling-related markers in cancer patients with bone metastasisBiomarkers200813221723618270872
   PubMed Web of Science ®Google Scholar
• O’BrienPJRamanathanRYinglingJMAnalysis and variability of TGFbeta measurements in cancer patients with skeletal metastasesBiologics20082356356919707386
   PubMedGoogle Scholar
• ClassenSMuthCDebey-PascherSApplication of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR therapyPharmacogenet Genomics201020314715620084050
   PubMed Web of Science ®Google Scholar
• KadamSCleverlyALFarmenMGrondinJCoxYILahnMA canonical transforming growth factor beta-dependent signaling pathway is present in peripheral blood cells of cancer patients with skeletal metastasisJ Mol Biomark Diagn201343153161
   Google Scholar
• KanjilalVYinglingJMYanLIntegrative analysis of genomic RNA expression data from in vitro and in vivo models of TGF-beta receptor kinase inhibitors to identify novel informative biomarkers of TGF-beta signalingCancer Res20061204
   Google Scholar
• DuanKKanjilalVYanLYinglingJPatelKShouJGenomic analysis of TGFβ treated cell lines with phenotypically distinct outcomes to identify transcriptional signatures for assessment in stratification of cancersPresented at: First AACR Centennial Conference on Translational Cancer MedicineNov 4–8; 2007Singapore Abstract B57
   Google Scholar
• Calvo-AllerEBaselgaJGlattSFirst human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase. Poster presented at: ASCO Annual Meeting; 2008; Chicago, ILJ Clin Oncol Abstract 14554
   Google Scholar
• Rodon AhnertJBaselgaJCalvoEFirst human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. Presented at: ASCO Annual Meeting; 2011; Chicago, ILJ Clin Oncol Abstract 3011
   Google Scholar
• AzaroABaselgaJSepúlvedaJMThe oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: the first human dose study. Poster presented at: ASCO Annual Meeting; 2012; Chicago, ILJ Clin Oncol Abstract Number 2042
   Google Scholar
• RodonJCarducciMASepúlvedaJMIntegrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, LY2157299 monohydrate (LY)Presented at: ASCO Annual Meeting2013Chicago, IL Abstract 2016
   Google Scholar
• KovacsRJMaldonadoGAzaroACardiac safety of TGF-beta receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose studyCardiovasc Toxicol Epub201412910.1007/s12012-014-9297-4
   Web of Science ®Google Scholar
• AzaroARodonJCarducciMCase series of cancer patients treated with galunisertib, a transforming growth factor-beta receptor I kinase inhibitor in a first-in-human dose studyJ Med Cases2014511603609
   Google Scholar
• RodonJCarducciMSepulveda-SanchezJMPharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancerInvest New Drugs201533235737025529192
   PubMed Web of Science ®Google Scholar
• RodonJCarducciMASepulveda-SanchezJMFirst-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and gliomaClin Cancer Res201521355356025424852
   PubMed Web of Science ®Google Scholar
• Sepulveda-SanchezJRamosAHilarioAAssessment of changes in brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with the combination of lomustine and the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrateOncology Lett20159624422448
   Web of Science ®Google Scholar
• GrassianARLinFBarrettRIsocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT)J Biol Chem201228750421804219423038259
   PubMed Web of Science ®Google Scholar
• VerhaakRGHoadleyKAPurdomEIntegrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell20101719811020129251
   PubMed Web of Science ®Google Scholar
• AnidoJSaez-BorderiasAGonzalez-JuncaATGF-beta receptor inhibitors target the CD44 (high)/Id1 (high) glioma-initiating cell population in human glioblastomaCancer Cell201018665566821156287
   PubMed Web of Science ®Google Scholar
• BrunaADarkenRSRojoFHigh TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B geneCancer Cell200711214716017292826
   PubMed Web of Science ®Google Scholar
• HolzerTRGustavsonMPinardRDevelopment and analytical validation of a quantitative tissue-based assay for phospho-Smad2 (Ser465/467) in glioblastoma multiforme: a potential biomarker of TGF-β pathway activationPresented at: 100th Annual Meeting2011San Antonio, TX
   Google Scholar
• KuczynskiEAPattenSGCoomberBLVEGFR2 expression and TGF-beta signaling in initial and recurrent high-grade human gliomaOncology201181212613421985798
   PubMed Web of Science ®Google Scholar
• LohJKLieuASSuYFPlasma levels of transforming growth factor-beta 1 before and after removal of low- and high-grade astrocytomasCytokine201361241341823260996
   PubMed Web of Science ®Google Scholar
• PenuelasSAnidoJPrieto-SanchezRMTGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastomaCancer Cell200915431532719345330
   PubMed Web of Science ®Google Scholar
• HardeeMEMarciscanoAEMedina-RamirezCMResistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-betaCancer Res201272164119412922693253
   PubMed Web of Science ®Google Scholar
• ZhangMHerionTWTimkeCTrimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-beta receptor I kinase inhibitor LY2109761Neoplasia201113653754921677877
   PubMed Web of Science ®Google Scholar
• ZhangMKleberSRohrichMBlockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastomaCancer Res201171237155716722006998
   PubMed Web of Science ®Google Scholar
• ParsonsSSawyerSYanLThe combination of the small molecule TGFβR1 inhibitor, LY2157299 monohydrate, with CCNU substantially blocks SMAD phosphorylation and significantly suppresses human glioblastoma xenograft growth. Presented at: Proceedings of the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 12–16; 2011; San Francisco, CAMol Cancer Ther Abstract C201
   Google Scholar
• US Food Drug AdministrationSearch Orphan Drug Designations and ApprovalsSilver Spring (MD)US Food and Drug Administration2013 [updated April 1, 2013]. Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=378712Accessed March 3, 2015
   Google Scholar
• Eli Lilly and CompanyA phase 2 study of LY2157299 monohydrate monotherapy or LY2157299 monohydrate plus lomustine therapy compared to lomustine monotherapy in patients with recurrent glioblastoma2012 [updated April 19, 2012]. Available from: https://clinicaltrials.gov/ct2/show/NCT01582269?term=NCT01582269&rank=1. NLM identifier: NCT01582269Accessed March 3, 2015
   Google Scholar
• Eli Lilly and CompanyPhase 1b/2a study combining LY2157299 with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma Available from: https://clinicaltrials.gov/ct2/show/NCT01220271?term=NCT01220271&rank=1. NLM identifier: NCT01220271Accessed March 3, 2015
   Google Scholar
• CarpentierAFBrandesAAKesariSSafety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progressionAnnual Meeting of the American Society of Clinical Oncology2013Chicago, IL Abstract Number 2061
   Google Scholar
• WickWSuarezCRodonJPhase 1b/2a study evaluating safety, pharmacokinetics (PK) and preliminary pharmacodynamics responses of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomasPoster presented at: 18th Annual SNO Scientific Meeting and Education DayNovember 22; 20132013Society of NeurooncologySan Francisco, CA
   Google Scholar
• Abou-ShadyMBaerHUFriessHTransforming growth factor betas and their signaling receptors in human hepatocellular carcinomaAm J Surg1999177320921510219856
   PubMed Web of Science ®Google Scholar
• MatsuzakiKDateMFurukawaFRegulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in human hepatocellular carcinoma: implications for roles of smads in its growthHepatology200032221822710915727
   PubMed Web of Science ®Google Scholar
• SaccoRLeuciDTortorellaCTransforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinomaCytokine200012681181410843770
   PubMed Web of Science ®Google Scholar
• GiannelliGBergaminiCFransveaESgarraCAntonaciSLaminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinomaGastroenterology200512951375138316285938
   PubMed Web of Science ®Google Scholar
• GiannelliGVillaELahnMTransforming growth factor-beta as a therapeutic target in hepatocellular carcinomaCancer Res20147471890189424638984
   PubMed Web of Science ®Google Scholar
• FransveaEAngelottiUAntonaciSGiannelliGBlocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cellsHepatology20084751557156618318443
   PubMed Web of Science ®Google Scholar
• FransveaEMazzoccaAAntonaciSGiannelliGTargeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinomaHepatology200949383985019115199
   PubMed Web of Science ®Google Scholar
• MazzoccaAFransveaELavezzariGAntonaciSGiannelliGInhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulationHepatology20095041140115119711426
   PubMed Web of Science ®Google Scholar
• GarbayDSerovaMSerrateCSpecific TGF-beta receptor-I inhibition using LY364947 impairs signaling, motility and invasion in parental and multikinase inhibitor-resistant hepatocarcinoma cellsPresented at: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics2010Berlin, Germany
   Google Scholar
• MazzoccaAFransveaEDituriFLupoLAntonaciSGiannelliGDown-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinomaHepatology201051252353419821534
   PubMed Web of Science ®Google Scholar
• FransveaEMazzoccaASantamatoAAzzaritiAAntonaciSGiannelliGKinase activation profile associated with TGF-beta-dependent migration of HCC cells: a preclinical studyCancer Chemother Pharmacol2011681798620844878
   PubMed Web of Science ®Google Scholar
• GiannelliGMazzoccaAFransveaELahnMAntonaciSInhibiting TGF-beta signaling in hepatocellular carcinomaBiochim Biophys Acta20111815221422321129443
   PubMed Web of Science ®Google Scholar
• SerovaMTijeras-RaballandADos SantosCEffects of TGF-beta signaling inhibition with LY2157299 in hepatocarcinoma models and in ex vivo whole tumor tissue samples from patient specimenPresented at: 104th annual meeting of the American Association for Cancer ResearchApril 6–10 2013Washington, DC, Philadelphia (PA) Abstract 2094
   Google Scholar
• Tijeras-RaballandASerovaMNeuzilletCLY2157299 w/wo sorafenib in hepatocarcinomas yields antitumor effects in transgenic mice and xenografts, also inhibiting Tgf-Β signalling in freshly-grown sliced tumor specimensPresented at: International Liver Cancer Association (ILCA) Annual Conference2014Kyoto; Japan Abstract P-005
   Google Scholar
• WangQYuTYuanYSorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signalJ Surg Oncol2013107442242722833259
   PubMed Web of Science ®Google Scholar
• SerovaMGarbayDRiveiroMETargeting of TGF-beta signaling results in decreased motility and invasion in parental and mulitkinase inhibitor-insensitive hepatocacinoma cellsPresented at: International Liver Cancer Association (ILCA) Annual Conference2011Brussels, Belgium
   Google Scholar
• SerovaMRiveiroMEde GramontATGF-β-RI kinase inhibitors, LY2157299 and LY364947, decrease motility and invasion in hepatocarcinoma (HCC) cells developing resistance to VEGFR/PDGFR kinase inhibitors. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 12–16; 2011; San Francisco, CAMol Cancer Ther Abstract Number B175
   Google Scholar
• Eli Lilly and CompanyPhase 2 study of LY2157299 in patients with hepatocellular carcinoma Available from: https://clinicaltrials.gov/ct2/show/NCT01246986?term=NCT01246986&rank=1. NLM identifier: NCT01246986Accessed March 3, 2015
   Google Scholar
• GiannelliGSantoroAKelleyRKPhase 2 study of the oral transforming growth factor-beta (TGF-beta) receptor I kinase inhibitor LY2157299Presented at: 7th ILCA (International Liver Cancer Association) Annual Conference2013Washington DC, USA
   Google Scholar
• FaivreSSantoroAKelleyRKA Phase 2 study of a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC)Presented at: Gastrointestinal Cancers Symposium2014San Francisco, CA
   Google Scholar
• TrutyMJUrrutiaRBasics of TGF-beta and pancreatic cancerPancreatology200775–642343517898532
   PubMed Web of Science ®Google Scholar
• MelisiDIshiyamaSSclabasGMLY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasisMol Cancer Ther20087482984018413796
   PubMed Web of Science ®Google Scholar
• LiZChangZChiaoLJTrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activationCancer Res200969197851785919773448
   PubMed Web of Science ®Google Scholar
• LonardoEHermannPCMuellerMTNodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapyCell Stem Cell20119543344622056140
   PubMed Web of Science ®Google Scholar
• OstapoffKTCenikBKWangMNeutralizing murine TGF-betaR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasisCancer Res201474184996500725060520
   PubMed Web of Science ®Google Scholar
• KozloffMCarboneroRNadalTPhase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohy-drate (LY) when combined with gemcitabine in patients with advanced cancerPresented at: ASCO Annual Meeting2013Chicago, IL Abstract 2563
   Google Scholar
• ZhouLNguyenANSohalDInhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDSBlood200811283434344318474728
   PubMed Web of Science ®Google Scholar
• ZhouLMcMahonCBhagatTReduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinaseCancer Res201171395596321189329
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyPhase 2/3 study of monotherapy LY2157299 monohydrate in very low-, low-, and intermediate-risk patients with myelodysplastic syndromes Available from: https://clinicaltrials.gov/ct2/show/NCT02008318?term=NCT02008318&rank=1. NLM identifier: NCT02008318Accessed March 3, 2015
   Google Scholar
• XuYTabeYJinLWattJTGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelomonocytic leukaemic cells co-cultured with stromal cellsBr J Haematol2008142219220118492113
   PubMed Web of Science ®Google Scholar
• BrenetFKermaniPSpektorRRafiiSScanduraJMTGFbeta restores hematopoietic homeostasis after myelosuppressive chemotherapyJ Exp Med2013210362363923440043
   PubMed Web of Science ®Google Scholar
• GeRKangYMcPhersonJYinglingJReissMTransforming growth factor β pathway antagonists inhibit human breast cancer metastases to lung and bonePresented at: AACR Meeting2007Los Angeles, CA Abstract 2231
   Google Scholar
• SerizawaMTakahashiTYamamotoNKohYCombined treatment with erlotinib and a transforming growth factor-beta type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cellsJ Thorac Oncol20138325926923334091
   PubMed Web of Science ®Google Scholar
• VazquezPFCarliniMJDaroquiMCTGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancerClin Exp Metastasis2013308993100723832740
   PubMed Web of Science ®Google Scholar
• RoepmanPSchlickerATaberneroJColorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transitionInt J Cancer2014134355256223852808
   PubMed Web of Science ®Google Scholar
• CalonAEspinetEPalomo-PonceSDependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiationCancer Cell201222557158423153532
   PubMed Web of Science ®Google Scholar
• ArteagaCLTandonAKVon HoffDDOsborneCKTransforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cellsCancer Res19884814389839043164252
   PubMed Web of Science ®Google Scholar
• ArteagaCLHurdSDWinnierARJohnsonMDFendlyBMForbesJTAnti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progressionJ Clin Invest1993926256925767504687
   PubMed Web of Science ®Google Scholar
• ReissMBarcellos-HoffMHTransforming growth factor-beta in breast cancer: a working hypothesisBreast Cancer Res Treat199745181959285120
   PubMed Web of Science ®Google Scholar
• KorpalMYanJLuXXuSLeritDAKangYImaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasisNat Med200915896096619597504
   PubMed Web of Science ®Google Scholar
• LacherMDTiirikainenMISaunierEFTransforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of coxsackie and adenovirus receptor in conjunction with reversal of epithelial-mesenchymal transitionCancer Res20066631648165716452224
   PubMed Web of Science ®Google Scholar
• TanARAlexeGReissMTransforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?Breast Cancer Res Treat2009115345349518841463
   PubMed Web of Science ®Google Scholar
• GanapathyVGeRGrazioliATargeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasisMol Cancer2010912220504320
   PubMed Web of Science ®Google Scholar
• WangEXiangBOlivaresMChungCArteagaCTransforming growth factor beta engages TACE/ADAM17 and ErbB3 to activate PI3K/Akt in HER2-overexpressing breast cancer and desensitizes cells to trastuzumab. Presented at: CTRC-AACR San Antonio Breast Cancer Symposium; San Antonio, CACancer Res2008
   Web of Science ®Google Scholar
• WangSEYuYCriswellTLOncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediatorsOncogene201029233335334820383197
   PubMed Web of Science ®Google Scholar
• WangKFengHRenWBMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231J Cancer Res Clin Oncol2011137111687169621892652
   PubMed Web of Science ®Google Scholar
• BholaNEBalkoJArteagaCInhibition of the TGFβ pathway inhibits chemotherapy-induced enrichment of breast cancer stem cells in triple-negative breast cancerPoster presented at: AACR Annual Meeting2012Chicago, IL Abstract Number 3475
   Google Scholar
• ConnollyECSaunierEFQuigleyDOutgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761Cancer Res20117162339234921282335
   PubMed Web of Science ®Google Scholar
• ShariatSFAndrewsBKattanMWKimJWheelerTMSlawinKMPlasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasisUrology20015861008101511744478
   PubMed Web of Science ®Google Scholar
• ShariatSFKattanMWTraxelEAssociation of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progressionClin Cancer Res20041061992199915041717
   PubMed Web of Science ®Google Scholar
• ShariatSFSemjonowALiljaHSavageCVickersAJBjartellATumor markers in prostate cancer I: blood-based markersActa Oncol201150Suppl 1617521604943
   PubMed Web of Science ®Google Scholar
• WanXLiZGYinglingJMYangJEffect of transforming growth factor beta (TGF-beta) receptor I kinase inhibitor on prostate cancer bone growthBone201250369570322173053
   PubMed Web of Science ®Google Scholar
• CebonJSAnakaMHudsonCRole of cytokine-induced plasticity in melanoma on invasive, therapy-resistant cells that express EMT-related genes and pathways. Poster presented at ASCO Annual Meeting; 2012; Chicago. ILJ Clin Oncol Abstract 8542
   Google Scholar
• SunCWangLHuangSReversible and adaptive resistance to BRAF(V600E) inhibition in melanomaNature2014508749411812224670642
   PubMed Web of Science ®Google Scholar
• HanksBAHoltzhausenAEvansKHeidMBlobeGCCombinatorial TGF-beta signaling blockade and anti-CTLA4 antibody immunotherapy in a murine BRAFV600E-PTEN−/− transgenic model of melanoma. Presented at: ASCO Annual Meeting; 2014; Chicago, ILJ Clin Oncol Abstract 3011
   Google Scholar
• DeLongPCarrollRGHenryACRegulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinomaCancer Biol Ther20054334234615846066
   PubMed Web of Science ®Google Scholar
• BiswasSGuixMRinehartCInhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progressionJ Clin Invest200711751305131317415413
   PubMed Web of Science ®Google Scholar
• AnscherMSKongFMAndrewsKPlasma transforming growth factor beta1 as a predictor of radiation pneumonitisInt J Radiat Oncol Biol Phys1998415102910359719112
   PubMed Web of Science ®Google Scholar
• LapingNHuetSTGF-β receptor kinase inhibitors for the treatment of fibrosisDijkePHeldinC-HSmad Signal Transduction: Smads in Proliferation, Differentiation and Diseasethe NetherlandsSpringer Verlag2006443459
   Google Scholar
• FlechsigPDadrichMBickelhauptSLY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signalsClin Cancer Res201218133616362722547771
   PubMed Web of Science ®Google Scholar